My NCBISign In

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser, and may not function properly. More information here...

    Results: 1 to 20 of 265

    1.

    Low-dose naltrexone therapy improves active Crohn's disease.

    Smith JP, Stock H, Bingaman S, Mauger D, Rogosnitzky M, Zagon IS.

    Am J Gastroenterol. 2007 Apr;102(4):820-8. Epub 2007 Jan 11.

    PMID:
    17222320
    [PubMed - indexed for MEDLINE]

    Related citations

    2.

    Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo-controlled trial.

    Smith JP, Bingaman SI, Ruggiero F, Mauger DT, Mukherjee A, McGovern CO, Zagon IS.

    Dig Dis Sci. 2011 Jul;56(7):2088-97. Epub 2011 Mar 8.

    PMID:
    21380937
    [PubMed - indexed for MEDLINE]

    Related citations

    3.

    Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries.

    Lichtenstein GR, Yan S, Bala M, Hanauer S.

    Am J Gastroenterol. 2004 Jan;99(1):91-6.

    PMID:
    14687148
    [PubMed - indexed for MEDLINE]

    Related citations

    4.

    Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.

    Borrelli O, Bascietto C, Viola F, Bueno de Mesquita M, Barbato M, Mancini V, Bosco S, Cucchiara S.

    Dig Liver Dis. 2004 May;36(5):342-7.

    PMID:
    15191204
    [PubMed - indexed for MEDLINE]

    Related citations

    5.

    Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study.

    Asteria CR, Ficari F, Bagnoli S, Milla M, Tonelli F.

    Scand J Gastroenterol. 2006 Sep;41(9):1064-72.

    PMID:
    16938720
    [PubMed - indexed for MEDLINE]

    Related citations

    6.

    Infliximab improves quality of life in the short-term in patients with fistulizing Crohn's disease in clinical practice.

    Cadahia V, García-Carbonero A, Vivas S, Fuentes D, Niño P, Rebollo P, Rodrigo L.

    Rev Esp Enferm Dig. 2004 Jun;96(6):369-74; 374-8. English, Spanish.

    PMID:
    15230666
    [PubMed - indexed for MEDLINE]
    Free Article

    Related citations

    7.

    The effects of infliximab maintenance therapy on health-related quality of life.

    Feagan BG, Yan S, Bala M, Bao W, Lichtenstein GR.

    Am J Gastroenterol. 2003 Oct;98(10):2232-8.

    PMID:
    14572573
    [PubMed - indexed for MEDLINE]

    Related citations

    8.

    Trichuris suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease.

    Summers RW, Elliott DE, Qadir K, Urban JF Jr, Thompson R, Weinstock JV.

    Am J Gastroenterol. 2003 Sep;98(9):2034-41.

    PMID:
    14499784
    [PubMed - indexed for MEDLINE]

    Related citations

    9.

    Oral naltrexone to enhance analgesia in patients receiving continuous intrathecal morphine for chronic pain: a randomized, double-blind, prospective pilot study.

    Hamann S, Sloan P.

    J Opioid Manag. 2007 May-Jun;3(3):137-44.

    PMID:
    18027539
    [PubMed - indexed for MEDLINE]

    Related citations

    10.

    Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.

    Colombel JF, Sandborn WJ, Rutgeerts P, Kamm MA, Yu AP, Wu EQ, Pollack PF, Lomax KG, Chao J, Mulani PM.

    Am J Gastroenterol. 2009 May;104(5):1170-9. Epub 2009 Apr 7.

    PMID:
    19352339
    [PubMed - indexed for MEDLINE]

    Related citations

    11.

    Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study.

    Peyrin-Biroulet L, Laclotte C, Bigard MA.

    Aliment Pharmacol Ther. 2007 Mar 15;25(6):675-80.

    PMID:
    17311600
    [PubMed - indexed for MEDLINE]
    Free Article

    Related citations

    12.

    Health-related quality of life during natalizumab maintenance therapy for Crohn's disease.

    Feagan BG, Sandborn WJ, Hass S, Niecko T, White J.

    Am J Gastroenterol. 2007 Dec;102(12):2737-46.

    PMID:
    18042106
    [PubMed - indexed for MEDLINE]

    Related citations

    13.

    Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease.

    Mantzaris GJ, Christidou A, Sfakianakis M, Roussos A, Koilakou S, Petraki K, Polyzou P.

    Inflamm Bowel Dis. 2009 Mar;15(3):375-82.

    PMID:
    19009634
    [PubMed - indexed for MEDLINE]
    Free Article

    Related citations

    14.

    Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease.

    Yacyshyn BR, Barish C, Goff J, Dalke D, Gaspari M, Yu R, Tami J, Dorr FA, Sewell KL.

    Aliment Pharmacol Ther. 2002 Oct;16(10):1761-70.

    PMID:
    12269969
    [PubMed - indexed for MEDLINE]
    Free Article

    Related citations

    15.

    A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease.

    Dotan I, Rachmilewitz D, Schreiber S, Eliakim R, van der Woude CJ, Kornbluth A, Buchman AL, Bar-Meir S, Bokemeyer B, Goldin E, Maaser C, Mahadevan U, Seidler U, Hoffman JC, Homoky D, Plasse T, Powers B, Rutgeerts P, Hommes D; Semapimod-CD04/CD05 Investigators.

    Gut. 2010 Jun;59(6):760-6.

    PMID:
    20551461
    [PubMed - indexed for MEDLINE]

    Related citations

    16.

    Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease.

    Folwaczny C, Wiebecke B, Loeschke K.

    Am J Gastroenterol. 1999 Jun;94(6):1551-5.

    PMID:
    10364024
    [PubMed - indexed for MEDLINE]

    Related citations

    17.

    Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn's disease.

    Reilly MC, Gerlier L, Brabant Y, Brown M.

    Clin Ther. 2008 Feb;30(2):393-404.

    PMID:
    18343277
    [PubMed - indexed for MEDLINE]

    Related citations

    18.

    Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab.

    Sands BE, Kozarek R, Spainhour J, Barish CF, Becker S, Goldberg L, Katz S, Goldblum R, Harrigan R, Hilton D, Hanauer SB.

    Inflamm Bowel Dis. 2007 Jan;13(1):2-11.

    PMID:
    17206633
    [PubMed - indexed for MEDLINE]
    Free Article

    Related citations

    19.

    Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial.

    Hinojosa J, Gomollón F, García S, Bastida G, Cabriada JL, Saro C, Ceballos D, Peñate M, Gassull MA; Spanish Scientific Group on Crohn's Disease and Ulcerative Colitis.

    Aliment Pharmacol Ther. 2007 Feb 15;25(4):409-18.

    PMID:
    17269996
    [PubMed - indexed for MEDLINE]
    Free Article

    Related citations

    20.

    Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial.

    Loftus EV, Feagan BG, Colombel JF, Rubin DT, Wu EQ, Yu AP, Pollack PF, Chao J, Mulani P.

    Am J Gastroenterol. 2008 Dec;103(12):3132-41. Epub 2008 Oct 3. Erratum in: Am J Gastroenterol. 2009 Jul;104(7):1894.

    PMID:
    18853973
    [PubMed - indexed for MEDLINE]

    Related citations

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Filters: Manage Filters

      Find related data

      Recent activity

      You are here: NCBI > Literature > PubMed
      Write to the Help Desk